文献速递自身炎症与 IgG4 相关病

VEXAS综合征感染负担系统综述及预防策略

Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention.
PubMed 文献 · Lancet Rheumatol · 2025-09-04

该系统综述纳入57项研究共813例VEXAS综合征患者,发现感染常见且40-60%为重症、6-15%为致死性;肺部感染最常见,机会性病原体即使在未接受免疫抑制治疗者中也频繁报告,提示固有免疫功能障碍;作者建议对高风险患者考虑复方磺胺甲噁唑和伐昔洛韦预防,并推荐接种肺炎链球菌、水痘-带状疱疹病毒、流感和SARS-CoV-2疫苗。

要点

  • VEXAS综合征患者感染常见,40-60%为重症,6-15%为致死性。
  • 肺部感染最常见,机会性病原体在未接受免疫抑制治疗者中也有报告。
  • 作者建议对高风险患者考虑复方磺胺甲噁唑和伐昔洛韦预防,并推荐接种疫苗。

核心结论

  • VEXAS综合征患者感染负担重,需将感染风险纳入管理,并需在前瞻性研究中评估预防策略。

研究设计与样本

  • 系统综述,纳入57项研究共813例VEXAS综合征患者。

主要发现

  • VEXAS综合征患者感染频繁,40-60%的病例为重症,6-15%的病例为致死性。
  • 肺部感染最常见,其次为皮肤感染和菌血症。
  • 机会性病原体如耶氏肺孢子菌、嗜肺军团菌、非结核分枝杆菌和水痘-带状疱疹病毒频繁报告,即使在未接受免疫抑制治疗的患者中也是如此,提示固有免疫功能障碍。

关键数值与推荐

  • 作者建议对高风险感染患者(包括接受免疫抑制治疗者以及有淋巴细胞减少、pMet41Val突变或既往严重或反复感染者)特别考虑复方磺胺甲噁唑(或其他肺孢子菌预防药物,如阿托伐醌或喷他脒)和伐昔洛韦预防。
  • 作者提出,对于正在服用阿扎胞苷的中性粒细胞减少患者,泊沙康唑可能适用。
  • 推荐接种针对肺炎链球菌、水痘-带状疱疹病毒、流感和SARS-CoV-2的疫苗。

临床怎么用

  • 作者建议对高风险感染患者特别考虑复方磺胺甲噁唑和伐昔洛韦预防。
  • 作者提出正在服用阿扎胞苷的中性粒细胞减少患者使用泊沙康唑可能适用。
  • 作者推荐接种肺炎链球菌、水痘-带状疱疹病毒、流感和SARS-CoV-2疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infections are increasingly recognised as a major cause of morbidity and mortality in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. We conducted a systematic review to characterise the infectious burden of VEXAS syndrome and propose preventive strategies. We included 57 studies (813 patients) showing that infections in patients with VEXAS syndrome were frequent, severe in 40-60% of cases, and fatal in 6-15% of cases. Pulmonary infections were most common, followed by cutaneous infections and bacteraemia. Opportunistic pathogens, such as Pneumocystis jirovecii, Legionella pneumophila, non-tuberculous mycobacteria, and varicella zoster virus, were frequently reported, even in patients not receiving immunosuppressive therapy, which suggests intrinsic immune dysfunction. Prophylaxis with co-trimoxazole (or other Pneumocystis prophylaxis, such as atovaquone or pentamidine) and valaciclovir should particularly be considered for patients at high risk of infection, including those receiving immunosuppressive therapy and those with lymphopenia, pMet41Val mutation, or previous severe or recurrent infections. Posaconazole might be appropriate in patients with neutropenia who are taking azacitidine. Vaccination against Streptococcus pneumoniae, varicella zoster virus, influenza, and SARS-CoV-2 is recommended. These data highlight the need to integrate infectious risk into VEXAS syndrome management and to evaluate preventive strategies in prospective studies.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ribier V, Hadjadj J, Jachiet V, et al. Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention. Lancet Rheumatol. 2025. PMID: 40915301. doi:10.1016/S2665-9913(25)00225-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。